Satellos Bioscience (NASDAQ:MSLE) Stock Lifted to “Sell” by Wall Street Zen

Wall Street Zen upgraded shares of Satellos Bioscience (NASDAQ:MSLE) from a strong sell rating to a sell rating in a research note published on Saturday,Wall Street Zen reports.

A number of other equities analysts also recently weighed in on MSLE. HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Satellos Bioscience in a research report on Monday, August 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Satellos Bioscience in a research report on Wednesday, November 4th. Craig Hallum assumed coverage on Satellos Bioscience in a research report on Thursday, October 8th. They issued a “buy” rating and a $24.00 price objective for the company. Finally, Zacks Research downgraded Satellos Bioscience from a “hold” rating to a “strong sell” rating in a research note on Wednesday, October 21st. Six analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $20.60.

Satellos Bioscience Stock Down 2.9%

Shares of MSLE stock traded down $0.20 on Friday, reaching $6.63. The stock had a trading volume of 47,722 shares, compared to its average volume of 46,458. The firm’s 50-day moving average is $7.77 and its two-hundred day moving average is $8.19. The firm has a market capitalization of $140.69 million, a price-to-earnings ratio of -3.17 and a beta of 1.63. Satellos Bioscience has a 12 month low of $5.30 and a 12 month high of $13.39.

Satellos Bioscience (NASDAQ:MSLE) last issued its earnings results on Thursday, November 12th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.09). On average, sell-side analysts forecast that Satellos Bioscience will post -1.86 earnings per share for the current fiscal year.

Institutional Trading of Satellos Bioscience

An institutional investor recently raised its stake in Satellos Bioscience stock. Stonepine Capital Management LLC boosted its position in Satellos Bioscience Inc. (NASDAQ:MSLE) by 391.6% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 491,624 shares of the company’s stock after purchasing an additional 391,624 shares during the quarter. Satellos Bioscience comprises about 0.0% of Stonepine Capital Management LLC’s portfolio, making the stock its 16th biggest holding. Stonepine Capital Management LLC owned approximately 2.36% of Satellos Bioscience worth $3,723,291 at the end of the most recent reporting period.

About Satellos Bioscience

Satellos Bioscience is a biotechnology company developing treatments intended to improve the body’s ability to repair and regenerate muscle. Its research focuses on muscle stem cells and the cellular processes that guide their function. The company’s lead program, SAT-3247, is an investigational oral small-molecule therapy being developed for Duchenne muscular dystrophy. Satellos is studying whether its approach can restore muscle stem-cell activity and support muscle regeneration; the candidate remains in development and is not an approved treatment.